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ABSTRACT
Several gene signatures have been proposed in the past two decades to
improve outcome prediction for breast cancer patients and to guide
treatment decisions. Current treatment guidelines, however, primarily focus
on established clinicopathological features. In Paper I, we identified a novel
18-marker gene expression signature predicting breast cancer-specific
survival. The 18-marker signature was validated in three independent cohorts
and showed increased predictive power over the clinically validated Oncotype
Dx signature.
Despite increasing survival rates, about 6-23% of patients suffer from
recurrences within five years of initial diagnosis indicating treatment failure. 
It is highly important to differentiate between clonally related recurrences
and independent primary tumours due to potentially differing prognoses and
treatment regimes. Currently, there is no consensus on how to define clonal
relatedness between multiple tumours in the same patient. In Paper II, we
identified the Similarity Index (SI) as the most reliable tool to classify tumour
clonality.
The mammary gland is known to be highly sensitive to radiation, especially at
a young age. In the years from 1920-1965, a total of 17,200 female Swedish
infants were treated with ionizing radiation for skin haemangioma, resulting
in an increased risk of developing breast cancer. In Paper III, we analysed 
breast tumours for genomic instability, which can be induced by ionizing
radiation. Patients with higher absorbed doses to the breast exhibited
increased genomic instability compared to patients exposed to lower
absorbed doses. These results strongly suggest radiation-induced genomic
instability as a biological link between ionizing radiation exposure at a young 
age and the increased breast cancer risk in subsequent decades.
In conclusion, this work highlights the importance of complementing
established clinicopathological features with molecular biology and statistical 
models to improve breast cancer risk assessment and personalize treatment 
strategies.
Keywords: breast cancer, gene signature, molecular biomarkers, tumour
clonality, genomic instability, Swedish haemangioma cohort
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1 INTRODUCTION
1.1 Cancer
Cancer defines a heterogeneous group of diseases caused by uncontrolled cell 
growth with the potential to spread to other parts of the body. The
transformation of normal cells into tumour cells is termed carcinogenesis and
typically progresses from a pre-cancerous lesion to a malignant tumour. The
risk of developing cancer is increased by specific genetic factors and external
agents, including physical carcinogens (e.g. ultraviolet and ionizing radiation),
chemical carcinogens (e.g. tobacco smoke), and biological carcinogens, such
as infections from certain viruses or bacteria [1]. The World Health
Organization estimated about 18 million new cases of cancer globally in 2018
with more than 9 million cancer-related deaths, making cancer the second 
leading cause of death worldwide [2]. 
1.1.1 Cancer as a genetic disease
Cancer is a disease of the genome where each patient’s tumour encompasses
a unique combination of genetic and epigenetic changes, such as DNA
mutations, DNA copy number alterations (CNAs) and epigenetic modifications
of DNA and histone proteins. Alterations that confer selective growth
advantages to cancer cells are driver mutations, which induce and promote
carcinogenesis by activating proto-oncogenes, inactivating tumour
suppressor genes, or altering DNA repair genes. A typical tumour contains
two to eight driver mutations [3]. The remaining mutations are passenger
mutations that do not provide a growth advantage, but were generated in an 
ancestor cancer cell during the acquisition of driver mutations [3, 4]. 
Consequently, tumour genomes are characterized by a high frequency of 
genetic alterations, where most alterations do not cause cancer but are rather
a result of uncontrolled cell division [5]. 
1.1.2 Genomic heterogeneity
The majority of cancers accumulate sequential somatic alterations that are
developed over the course of 20-30 years [3]. Driver alterations primarily
affect signalling pathways that regulate cell fate determination, cell survival,
and genome maintenance [3]. Specific driver and passenger mutations differ
between individual tumours, but usually involve the same pathways [3]. In
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contrast to acquired mutations, inherited mutations play a major role in 
about 5-10% of all cancers and predispose individuals to develop specific 
types of cancer [6].  
Genomic heterogeneity can be observed in tumours from different patients 
and multiple tumours from the same patient (intertumour heterogeneity). 
Even within one tumour, different cell populations may exist that harbour 
unique genetic alterations (intratumour heterogeneity) [7]. Intratumour 
heterogeneity can be identified in most cancers and is considered a major 
problem affecting the accuracy of tumour diagnosis, as single biopsies will not 
reflect the pathology of the tumour adequately [7]. Thus, intratumour 
heterogeneity can facilitate the expansion of drug-resistant populations and 
potentially affect treatment response of metastases (Figure 1) [3, 7]. 
1.2 Breast cancer
1.2.1 The female breast
The female breast consists of glandular, adipose and connective tissue 
distributed in varying amounts and proportions (Figure 2). When fully 
developed, the glandular tissue includes 15-20 lobes composed of lobules, 
which contain clusters of alveoli [8]. The lobes, lobules, and alveoli are linked 
by a network of ducts converging on the nipple [8]. Ducts and lobules are 
composed of luminal epithelial and myoepithelial cell layers [9]. During 
lactation, the inner luminal epithelial cells of the terminal ducts and the 
Figure 1. Intratumour heterogeneity can lead to the expansion of certain subpopulations of a 
tumour. Some tumour cells acquire the ability to infiltrate into the surrounding tissues and 
spread via blood or lymph circulation far beyond the original tumour to form distant 
metastases. Adapted from Navin, 2015.  
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lobules produce milk [9]. The outer myoepithelial cells assist in milk ejection
and play a role in maintaining the normal structure and function of the lobule
and basement membrane [9]. Other components of the breast are lymph
vessels, which carry the lymph fluid between lymph nodes forming a network
throughout the body to filter lymph and store white blood cells [10, 11]. 
Clusters of lymph nodes are located near the breast in the axilla, above the
collarbone, and in the chest [11]. Additionally, blood vessels and nerves can 
be found in the breast.
1.2.2 Epidemiology and risk factors
Breast cancer is the most common type of cancer in women (24.2%) with an
estimated number of more than 2 million new cases worldwide in 2018 [2]. 
According to the World Health Organization, breast cancer is the leading 
global cause of cancer-related death among women (15%) with
Figure 2. Anatomy of the female breast with cross sections of lobes and ducts. Adapted from
https://www.teresewinslow.com. 
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approximately 627,000 breast cancer-related deaths in 2018 [2]. Since the 
late 1980s, mortality rates have declined in most developed countries due to 
improved detection, earlier diagnosis, and more effective treatments [12]. 
Risk factors for developing breast cancer include female gender, increased 
age, obesity, alcohol consumption, increased breast tissue density, prior 
hormone replacement therapy, exposure to ionizing radiation, prior 
incidence of breast cancer, changes in breast cancer susceptibility genes, 
increased amounts of endogenous oestrogen through menstrual history 
(early menarche/late menopause), nulliparity, and older age at first child birth 
[11]. Familial predisposition accounts for about 5-10% of breast cancer cases 
in which the high-risk genes BRCA1 and BRCA2 play a major role [12]. 
However, the risk of developing breast cancer depends on a combination of 
factors, including family history as well as reproductive and lifestyle factors 
[12]. 
1.2.3 Breast pathology
Breast cancer is a clinically, genetically and histologically heterogeneous 
disease. There are more than 20 histological subtypes of breast cancer. Most 
breast cancers arise from glandular epithelial cells (termed carcinomas) and 
are subdivided into in situ and invasive lesions. In the case of in situ 
carcinomas, intraductal malignant epithelial cells are restricted to the ducts 
surrounded by an intact myoepithelial cell layer and thus not invading the 
surrounding tissues. Approximately 70% of invasive carcinomas are 
categorized as “no special type” (previously known as “invasive ductal 
carcinoma”) comprising a heterogeneous group of tumours that show no 
specific morphological features [12]. The most common of the special 
subtypes include lobular carcinoma, tubular carcinoma, mucinous carcinoma, 
carcinoma with medullary and apocrine features, etc. [12]. 
Several histopathological tools are routinely used in the clinic to guide 
treatment decisions. The histological assessment of tumour grade provides 
powerful prognostic information by analysing how closely a tumour 
resembles its tissue of origin based on tubular formation, nuclear 
differentiation, and cell proliferation. High-grade tumours tend to be more 
aggressive and display an unfavourable prognosis. Another powerful and 
well-established pathological tool is the tumour-node-metastasis (TNM) 
staging system, which takes into account the size of the tumour, spread to 
the lymph nodes, and the occurrence of distant metastases [13]. Nonetheless, 
patients with a similar type, grade, or TNM stage of breast cancer still respond 
differently to therapy and differ in clinical outcome. 
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1.2.4 Biomarkers for breast cancer
The expression of the oestrogen receptor (ER), progesterone receptor (PR),
human epidermal growth factor receptor 2 (HER2), and Ki-67 is routinely
evaluated to select the most appropriate treatment for breast cancer
patients. The hormone oestrogen (17β-estradiol) affects proliferation,
differentiation, and function of the mammary gland by binding to its
receptors, ERα and ERβ, among others. The activated ER translocates into the
nucleus and functions as a DNA-binding transcription factor to regulate gene
transcription. Currently, only ERα is clinically measured for treatment
decisions [14]. The ER induces PR expression, which is activated by the steroid
hormone progesterone. Overexpression of ER and PR predicts the likelihood
to benefit from endocrine therapy using adjuvant tamoxifen [15]. The ERBB2
proto-oncogene encodes the receptor tyrosine kinase erbB-2, also known as
HER2, and is amplified and/or overexpressed in approximately 15-20% of 
breast cancers [16, 17]. HER2 overexpression prognosticates increased
tumour aggressiveness and a higher incidence of recurrence [15]. 
Furthermore, HER2 overexpression is a predictive factor for response to
targeted therapy using the monoclonal antibody trastuzumab [15]. Ki-67 is a
cellular marker for proliferation that identifies ER-positive breast cancer
patients who would benefit from adjuvant chemotherapy [18]. Any new
biomarker needs to contribute clinically useful information beyond that
already provided by the current clinical and histopathological markers [19].
1.2.5 Molecular subtypes
Microarray-based gene expression profiling has shown that breast cancer
encompasses a collection of different diseases with unique patterns of gene
expression. Perou et al. [20] and Sorlie et al. [21] identified hierarchical
clusters based on gene expression that revealed the existence of intrinsic
breast cancer subtypes. The expression patterns of the intrinsic subtypes
overlap with the routinely evaluated biomarkers and highlight that ER-
positive and ER-negative breast cancers represent molecularly distinct
diseases (Table 1). The luminal subtypes (luminal A, luminal B/HER2-negative,
luminal B/HER2-amplified) encompass the hormone receptor-positive
tumours (i.e. ER- and PR-positive) and can be treated with endocrine therapy
resulting in good or intermediate prognoses. HER2-amplified subtypes
(luminal B/HER2-amplified, HER2-positive) offer a target for treatment with
trastuzumab but have more unfavourable prognoses. The triple-negative
subgroup has the worst prognosis as neither the hormone receptors nor HER2
can be targeted for treatment.
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Table 1. Intrinsic subtypes and associated biomarkers, treatment options and prognoses. 
Adapted from [22-24]. 
Luminal A 
Luminal B 
HER2-
negative 
Luminal B 
HER2-
amplified 
HER2-
positive 
Triple- 
negative 
ER + + + - - 
PR ± ± ± - - 
HER2 - - + + - 
Ki-67 <20% >20% any any any 
Treatment Endocrine Endocrine Endocrine, 
trastuzumab 
Trastuzumab Chemo-
therapy 
Prognosis Good Intermediate Intermediate Poor Poor 
1.2.6 Gene signatures
A gene signature comprises a set of genes representing distinct gene 
expression patterns, which are associated with clinical outcome (prognostic), 
response to a particular therapy (predictive), or distinguish phenotypically 
similar conditions (diagnostic). The 70-gene expression signature 
(MammaPrint) was identified from gene expression profiles of 117 breast 
tumours and predicted the occurrence of metastasis in lymph node-negative 
breast cancer patients more accurately than the established 
clinicopathological markers [25, 26]. The MINDACT trial demonstrated the 
clinical utility of the 70-gene signature to categorize high- and low-risk 
patients [27]. The 21-gene recurrence score (Oncotype Dx) is a clinically 
validated assay for ER+ and node-negative breast cancer patients to assess 
the risk of metastasis and predict the response to adjuvant chemotherapy 
[28, 29].  
A plethora of different gene expression signatures have been proposed for 
breast cancer, several of which mainly identify high-risk patients based on 
high expression of proliferation-related genes [30, 31]. Indeed, the 
identification of patients at risk for disease recurrence can guide treatment 
decisions to avoid adjuvant chemotherapy or, alternatively, select more 
aggressive therapy options. About 60% of early-stage breast cancer patients 
receive adjuvant chemotherapy, while only 2-15% of this patient group 
benefit from chemotherapy [32]. Consequently, treatment tailoring offers an 
opportunity to minimize the risk of toxic side effects by avoiding over-
treatment. 
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Despite many decades of developing prognostic gene signatures, a major
drawback of the field is the lack of consensus gene expression models for
prognosis [33]. Prognostic gene signatures aim to categorize a common set of
biological features but show surprisingly little overlap. However,
interpretation of gene expression signatures is difficult due to the complexity
of the underlying biological processes, as up to 30% of genes in any given
signature have unknown functions [33]. This complicates the identification of
affected pathways, which might consolidate single genes from different
signatures. Hence, linking gene signatures to underlying molecular 
mechanisms of cancer is crucial to enable translation into the clinic.
1.3 Survival analysis
Survival analysis is a branch of statistics analysing the expected time to an
event of interest, e.g. the death of a patient by any cause (OS; overall survival)
or the time from initial diagnosis to disease-specific death (DSS; disease-
specific survival). Since the event of interest is dichotomized, some parts of
the data might be censored (i.e. patients that have not experienced the event
by the time the study ends, patients lost to follow-up during the study period,
or patients that withdrew from the study) [34]. Survival data can be described
using the survival function S(t), which is defined as the probability of an
individual surviving from the time of origin to a specified time t [34]. These
survival probabilities for different values of t describe survival of the cohort
[35]. The hazard function h(t) is interconnected with the survival function and
gives the instantaneous potential of having an event at the time t, given that
the patient has survived up to time t [35]. The hazard function focusses on
the event occurring (current event rate) while the survivor function in
contrast focusses on the event not happening (cumulative non-occurrence) 
[34]. 
The hazard ratio (HR) measures the relative survival experience in two groups
over time, where HR = 1 means no difference in survival between the groups,
while HR >1 indicates increased mortality and HR <1 decreased mortality of 
the group [34, 35]. HRs are usually estimated using regression modelling
techniques, such as the Cox proportional hazards model (hereinafter referred
to as Cox model) [34, 36]. Cox models estimate the effects of a set of
covariates (i.e. known quantities potentially affecting prognosis) on survival,
while the baseline hazard h0(t) remains unspecified (semiparametric model)
[36, 37]. The proportional hazard assumption requires the HR to be constant
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contrast focusses on the event not happening (cumulative non-occurrence) 
[34]. 
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over time, where HR = 1 means no difference in survival between the groups, 
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while the baseline hazard h0(t) remains unspecified (semiparametric model) 
[36, 37]. The proportional hazard assumption requires the HR to be constant 
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over time, thus the hazard for one individual has to be proportional to the 
hazard for any other individual and independent of time [37]. Mathematically, 
the Cox model can be described using the following equation: 
ℎ(𝑡𝑡𝑡𝑡, X) = ℎ0(𝑡𝑡𝑡𝑡) exp�𝛽𝛽𝛽𝛽1X1 + … + 𝛽𝛽𝛽𝛽𝑝𝑝𝑝𝑝 X𝑝𝑝𝑝𝑝� 
where: 
• h(t, X) is the hazard at time t, considering covariates X
• h0(t) is the baseline hazard at time t 
• p is the number of covariates
• βp is the value of the pth Cox coefficient
• Xp is the value of the pth covariate.
In proportional hazard models, the HR is the exponentiated Cox coefficient exp(βp). The linear predictor η (eta) is represented by the product of the 
covariate vector X and the Cox coefficient β, where η >0 indicates a poor 
prognosis (high-risk group) and η <0 a favourable outcome (low-risk group). 
1.4 Predictive modelling
Generating a strong predictive model for patient survival is based on feature 
selection and model construction (Figure 3) [38]. Univariable Cox modelling 
can be used to estimate the utility of each probe (feature) of a gene 
expression microarray on an individual basis [38]. Sets of selected features 
can be used to build multivariable models that take the dependencies 
between the features into account [38, 39]. Iterative Bayesian model 
averaging (BMA) uses the weighted average of posterior distributions of 
multiple contending models and combines their effectiveness [38-40]. Hence, 
iterative BMA has the ability to account for model uncertainty and to select a 
small and parsimonious number of predictive features [38-40]. Iterative BMA 
represents a more accurate evaluation of feature importance than a P-value 
by implementing the posterior probability of each feature belonging in the 
model [40]. There are different ways to measure the quality of a model’s fit. 
The C-index (concordance index) is a scalar that represents the predictive 
discrimination of a fitted survival model and ranges from 0.5 (random 
prediction) to 1 (perfect discrimination) [41, 42]. 
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The time-dependent area under the receiver operating characteristic (ROC) 
curve function (AUC(t)) depicts the model’s ability to distinguish between
patients who experience the event from those who remain event-free [41]. 
The advantage of AUC(t) functions lies in the sequential description of
accuracy over time as opposed to the C-index, which gives a global overview
[41]. Predictive models should be validated to ensure that the model works
for new sets of patients that were not included in the training cohort used to
develop the model [43]. Evaluating model performance in external cohorts
can identify overfitted models as well as other deficiencies in model 
development, such as small sample size or incorrect handling of missing 
values [44]. External validation is the first step towards the establishment of
a model in clinical practice [45]. 
1.5 Tumour clonality
Cancer can be viewed from an evolutionary perspective as a genetically and
epigenetically heterogeneous population of individual cells reflecting both 
the development of cancer and the challenges in curing it [46, 47]. Clonal 
Figure 3. Identification of novel prognostic gene signatures. A, Selection of covariates (genes)
based on Cox models and iBMA resulted in a gene signature stratifying patients into different
risk groups. B, Validation of the gene signature in an independent validation cohort ensures 
universal applicability. Adapted from Zhao et al. (2012), and Reis-Filho and Pusztai (2011).
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tumour cell populations are defined as a set of cells that share similar genomic 
alterations arising from a common ancestor [47]. Tumour cells can gain the 
ability to invade other tissues and organs to generate new tumours 
(metastatic recurrence). Currently, there is no consensus on determining 
whether multiple tumours in the same patient are different entities that 
developed independently or a recurrence of the primary lesion (clonal 
relatedness; Figure 4). In clinical practice, the assessment of clonal 
relatedness is presently based on the concordance of histological tumour 
characteristics, such as histological subtype or hormone receptor status. 
Clonal evolution of tumours (also termed clonal relatedness or tumour 
clonality) describes the generation of genetically diverse cell populations 
through genomic instability resulting in distinct molecular features. 
Figure 4. Clonal relatedness of multiple tumours in the same patient. In clonal tumours, both 
tumours are directly related and aggressive treatment is required as the recurrent tumour 
probably contains resistant cells. If two tumours do not share clinicopathological and 
molecular features, the tumours emerged independently (no clonal relationship). Indirect 
clonal relatedness means that two tumours share some features due to their common 
precursor but also show differences (branching evolution). Adapted from 
www.unibas.ch/en/Research/Uni-Nova/Uni-Nova-128/Uni-Nova-128-New-treatment-
concepts-for-recurrent-lymphoma.html. 
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These features form in response to selective pressures of the tumour
microenvironment and neutral changes over time (subclonal drift) and
eventually lead to genetically distinct subpopulations [46, 48, 49]. 
Consequently, two tumours that are derived from the same tumour precursor
cell will share certain features, i.e. CNAs, genetic variants, DNA methylation
and gene expression patterns, in addition to nonmatching features that were
acquired over time [46, 50]. Determining the degree of similarity between
molecular features shared by both the primary tumour and the recurrence
permits classification of tumours as independent or clonally related [51]. 
Genetic similarities in certain tumour features might nevertheless be due to
genetic predisposition and shared environmental factors instead of indicating
metastatic spread or recurrence. Furthermore, some specific chromosomal 
aberrations are characteristic for certain cancer types and represent non-
random recurrent chromosomal aberrations [52]. Therefore, tumours that 
developed independently might also share common chromosomal
aberrations. To assess tumour clonality, tumour-specific genetic aberrations
need to be separated from the background of recurrent aberrations
frequently identified in the specific cancer type [53]. Hence, clonal tumours
are expected to share a higher degree of tumour-specific aberrations than can
be explained through cancer-specific recurrent aberrations or randomness
[53]. The discrimination between clonal and independent tumours is highly
important, as an independent primary tumour has a more favourable
prognosis than a recurrence [54, 55]. Thus, classification of a tumour as clonal 
or independent can affect the suitability of local or systemic therapy [54, 55]. 
1.6 Genomic instability in cancer
The evolution of a normal cell into a cancer cell requires multiple mutations,
which are rare events given the low mutation rate in normal cells [56, 57]. 
Models for tumour evolution suggest that mutations are acquired gradually
over time, eventually leading to more malignant stages of cancer [58]. 
However, the number of mutations commonly detected in tumours would be
too high to occur within a human life span [56, 57]. One theory to describe
this discrepancy is the mutator phenotype hypothesis, which proposes an 
elevated genome-wide acquisition of genomic aberrations as an early step in
carcinogenesis [57, 59, 60]. 
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These genomic aberrations can range from increased changes in DNA 
nucleotide sequence to large structural changes of chromosome fragments 
and whole genome duplication. Elevated numbers of repeats in repetitive 
DNA sequences are referred to as microsatellite instability [61], while 
chromosomal instability describes an elevated rate in the number of 
chromosomal aberrations (gain or loss of whole chromosomes, aneuploidy) 
and/or structural abnormalities (e.g. translocations, deletions, inversions, or 
duplications) [62-64]. Chromosomal instability is proposed to begin after at 
least 15-20% of the molecular time (from the last state of normal mammary 
development until diagnosis) has elapsed and is thus not considered the 
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activation of oncogenes, inactivation of tumour suppressor genes, reactive
oxygen species, chromothripsis, and breakage-fusion-bridge cycles induced
by telomere dysfunction or defective mitosis [63, 66]. Genomic instability
promotes inter- and intratumour heterogeneity and thereby enables the
adaptation of cancer cells to environmental stress potentially leading to a
more aggressive clinical behaviour and resistance to cancer therapies (Figure 
5) [63, 67]. Genomic instability can be acquired during carcinogenesis or
through germline mutations in genes responsible for genome integrity
leading to predisposition to cancer [68].
1.7 Chromothripsis
Carcinogenesis has generally been perceived as a multistep process, in which
cells accumulate somatic mutations over a long period of time [4]. 
Chromothripsis (from “chromo” (for “chromosome”) and “thripsis” (Greek for 
“shattering into pieces”)) presents a new paradigm of oncogenic
transformation via a single catastrophic event defined by the shattering of 
one or more chromosomes [69, 70]. Subsequently, the DNA fragments are
randomly reassembled forming a derivative chromosome [69, 70]. Typical
chromothripsis patterns show at least 10-50 shifts in CNAs on a single
chromosome oscillating between two or three copy number states [70]. 
Despite low prevalence in cancer (2-3%), chromothripsis occurs in almost all
cancer types and is associated with poor patient survival [69, 70]. 
The exact mechanisms leading to chromothripsis remain unclear but most 
hypotheses assume that chromothripsis acts on condensed chromosomes
explaining the highly localized shattering [69, 70]. Potential mechanisms for 
the induction of chromothripsis include: ionizing radiation damaging
condensed chromosomes [69]; telomere attrition leading to chromosome
end-to-end fusions followed by massive DNA breakage [69]; incomplete 
apoptosis followed by cell survival [71]; premature chromosome compaction,
i.e. condensation of chromosomes before completing DNA replication [72];
DNA shattering within a micronucleus followed by reassembly into a single
chromatid [70, 73]. Contrasting theories propose that chromothripsis events
are not necessarily restricted to localized shattering; instead, events involving
greater damage might be lethal and therefore not detected [74]. Accordingly,
local shattering might manifest the upper limit of what a cell can tolerate
without facing lethal consequences [74].
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1.8 Radiation as a carcinogen
Radiation is the emission of energy in the form of atomic particles or waves. 
Atomic particles include α- and β-radiation emitted from radioactive atoms, 
whereas waves include electromagnetic radiation, such as radio waves, 
microwaves, visible light, ultraviolet light, X-rays, and γ-radiation. Radiation 
with sufficiently high energy can lead to radiation-matter interactions, such 
as breaking chemical bonds, excitation of electrons, as well as ionization of 
atoms and molecules by removing electrons. Ionizing radiation includes both, 
atomic particles and electromagnetic waves, where γ-rays, X-rays, and the 
high-energy spectrum of ultraviolet light are considered ionizing. 
Approximately 300 million particles with ionizing properties pass through 
each person at sea level per hour [75]. Half of this normal background 
radiation comes from cosmic radiation; the other half from the decay of 
radioactive elements within the earth [75]. The amount of energy absorbed 
by living tissue is measured in gray (Gy), which is defined as one joule of 
energy absorbed per kilogram of mass. 
In tissues, ionizing radiation can cause DNA double-strand breaks (DSBs) and 
DNA hypomethylation among other types of cellular damage [76, 77]. DSBs 
can be induced directly by ionization of the sugar-phosphate backbone, or 
indirectly through the production of free radicals or reactive oxygen species 
(ROS) that can damage DNA [78, 79]. These genotoxic and carcinogenic 
properties of ionizing radiation can lead to chromosomal rearrangements and 
potentially cause severe long-term effects, such as genomic instability [77, 
80]. An unstable phenotype can persist through deficiencies in DNA repair 
and other disturbances in cellular homeostasis including oxidative stress [81-
84]. These effects are not limited to directly irradiated cells since genetic 
alterations, e.g. mutations, micronuclei formation, and chromosomal 
rearrangements, have been detected in non-irradiated cells surrounding 
irradiated cells (known as non-targeted or bystander effects) [81, 84, 85]. 
Radiation-induced genomic instability is described as an increased rate of 
genomic alterations initiated by ionizing radiation that persists after the 
exposure and ultimately promotes carcinogenesis [78, 84-87]. In addition, low 
doses (up to 0.1 Gy) have been shown to cause radiation-induced genomic 
instability [84]. The effects of ionizing radiation on humans vary by age and 
sex, with children and women being more radiosensitive [88, 89]. Especially, 
the mammary gland is known to be highly sensitive to radiation [90-93], 
particularly at a young age [88]. 
Introduction
15 
1.9 The Swedish haemangioma cohort
Infantile haemangiomas are benign vascular tumours that develop during the
first weeks of life and resolve without intervention in most cases [94]. The
Swedish haemangioma cohort consists of 17,200 women that were treated
with ionizing radiation for haemangiomas during 1920-1965 [95, 96]. The
infants were treated with encapsulated radium-226 needles that filtered α- 
and β-particles and allowed only γ-rays and subsequent radiation-matter
interactions to penetrate the tissue. The mean and median absorbed dose to
the breast were 0.18 and 0.04 Gy, respectively [95, 96]. In total, 877 cases of
breast cancer (5% of the cohort) were reported, representing an excess 
relative risk (ERR) of 0.48 Gy−1 of developing breast cancer at 50 years of age,
along with an excess absolute risk (EAR) of 10.4 (104 PYR Gy)−1 [95]. The ERR 
is the increase in risk over the background risk, while the EAR is the excess
risk expressed as the difference between total risk and background risk.
Previous studies on the Swedish haemangioma cohort showed that a two-
stage clonal expansion (TSCE) model incorporating radiation-induced
genomic instability at an early stage of carcinogenesis significantly improved
the description of the radiation risk [95, 97, 98]. However, this model was
built on epidemiological data and lacked the biological evidence of dose-
dependent genomic instability. 
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2 AIMS
The main objectives of this doctoral thesis are:
Paper I: To identify and validate a gene signature predicting breast cancer-
specific survival.
Paper II: To classify multiple invasive breast tumours from the same patient
as clonally related or independent based on different statistical methods and
molecular data.
Paper III: To screen breast carcinomas from patients exposed to ionizing
radiation in early childhood for genomic instability and investigate a potential
association with absorbed dose.
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3 PATIENTS AND METHODS 
3.1 Patients and tumour specimens
3.1.1 Paper I and II
The breast cancer patients included in Papers I and II were diagnosed in
Western Sweden between 1988 and 1999. After surgery, fresh-frozen tumour
samples were stored in the tumour bank at the Sahlgrenska University
Hospital Oncology Lab (Gothenburg, Sweden). Clinicopathological
information were obtained from Regional Cancer Centre West (Gothenburg,
Sweden), Sympathy and Melior databases (Sahlgrenska University Hospital). 
A subset of the tumours were stratified into different molecular breast cancer
subtypes (basal-like, luminal A, luminal B, and HER2/ER-) as described
elsewhere [99, 100]. Luminal B was further stratified according to the HER2
status determined by array comparative genomic hybridization (aCGH; log2
ratio ≥+0.5 for HER2+; and log2 ratio <+0.5 for HER2-) [23]. Routine
haematoxylin and eosin stained slides from formalin-fixed paraffin-
embedded (FFPE) samples were evaluated by a board certified breast
pathologist. Representative imprints from each tumour specimen were 
stained with May-Grünwald Giemsa (Chemicon) and evaluated for neoplastic
cells. Tumour specimens with at least 70% neoplastic cell content were 
included in downstream analyses.
In Paper I, 136 primary invasive breast carcinomas were selected from
previously analysed patient cohorts, mainly consisting of luminal B tumours
[100-102]. These 136 tumours formed the training cohort to identify the 18-
marker panel. For 79 breast tumours of the training cohort complete 
information on established clinicopathological features could be obtained. 
External validation was performed using gene expression data from three
publicly available datasets consisting of 1,085 breast cancer samples (Table
2). 
In Paper II, 74 invasive breast carcinomas corresponding to 37 patients with
two breast tumours each were selected for aCGH analysis. The patients were
stratified into four groups based on the anatomic location of the breast
tumours (ipsilateral or bilateral) and time interval between the diagnoses
(synchronous or metachronous). Metachronous disease was defined as a
time interval greater than six months between the two diagnoses. None of
the patients were diagnosed with distant metastasis at the time of diagnosis
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of either the first or second tumours. For ipsilateral breast tumours, only 
samples from opposite quadrants without nipple involvement were selected. 
Table 2. Overview of datasets used in Paper I. 
Dataset n (Subcohort) Platform Survival Clinical characteristics Ref. 
Training 
cohort 
136 (79) HumanHT-
12 Gene 
Expression 
BeadChip 
DSS; OS Age, number of positive 
axillary lymph nodes, 
histological grade, 
tumour size, ER, PR and 
HER2 status 
[100-
102] 
GSE1456 159 (128) Affymetrix 
Human 
Genome 
U133 
DSS; OS; 
RFS 
Molecular subtype, 
histological grade 
[103] 
GSE4922 
(Uppsala 
cohort) 
249 (237) Affymetrix 
Human 
Genome 
U133 
DFS Age, ER status, tumour 
size, axillary lymph node 
status, and histological 
grade 
[104] 
TCGA Breast 
Invasive 
Carcinoma 
dataset 
900 (720) mRNA-seq OS Number of positive 
axillary lymph nodes, 
tumour size, age, ER and 
PR status 
[105] 
3.1.2 Paper III 
The Swedish haemangioma cohort comprises 17,200 female patients that 
were treated for infantile haemangioma with radium-226 between 1920 and 
1965 [95, 96]. A total of 877 breast cancer cases were reported by December 
2009, estimating an excess relative risk at the age of 50 years of 0.48 Gy−1 and 
an excess absolute risk of 10.4 (104 PYR Gy)−1 [95]. Forty-six FFPE samples for 
primary breast carcinomas were selected for DNA extraction representing 
high- and low-dose cases in the cohort. In this study, patients exposed to 
absorbed doses to the breast <100 mGy were defined as the “low dose” and 
≥100 mGy as “high dose”. Tissue microarrays (TMAs) were used to determine 
the immunohistochemistry (IHC) subtype (luminal A, luminal B/HER2-
negative, luminal B/HER2-amplified, HER2 positive and triple-negative) with 
ER, PR, HER2, and Ki-67 immunostaining [23]. 
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3.2 Microarrays and sequencing
3.2.1 Gene expression microarray
Total RNA samples from 136 (Paper I) and 14 (Paper II) tumour specimens
were processed at the Swegene Center for Integrative Biology (SCIBLU, Lund
University, Sweden) using Illumina HumanHT-12 BeadChips (Illumina, CA,
USA). The expression microarrays contained about 49,000 probes
representing more than 25,400 RefSeq (Build 36.2, Release 22) and Unigene
(Build 199) annotated genes. Illumina HumanHT-12 gene expression profiles
were evaluated as described previously [100]. In brief, raw signal intensities
were preprocessed and quantile normalized using the BioArray Software
Environment (BASE) [106]. Further data processing was performed in Nexus
Expression 2.0 (BioDiscovery) using log2-transformed, normalized expression
values and a variance filter.
3.2.2 Array comparative genomic hybridization (aCGH) 
In Paper II, whole-genome tiling arrays with 38,043 BAC reporters (UCSC May
2004 hg17: NCBI Build 35) were manufactured as previously described [107]
at SCIBLU, Sweden. The clone set contained the 32K BAC clone library (BacPac
Resources), the 3.4K FISH Mapped Clones Version 1.3 (BacPac Resources),
clones located in telomeric regions [108], and clones covering microdeletion
syndromes [109]. Male genomic DNA was used as a reference for the aCGH
data. Data preprocessing and pin-based Lowess normalization were
performed using BASE [106]. 
Segmentation into regions of gains and losses was performed using the Rank
Segmentation algorithm with Nexus Copy Number Professional 7.5 software
(BioDiscovery; settings: 5.0E-5 significance threshold, 1000 kb maximum
contiguous probe spacing, minimum of 5 probes per segment). Minimal
common regions of copy number imbalances were identified when observed
in at least 25% of the tumour samples with a CNV overlap <99%. Segmented
data for the segment analysis were generated using the R-package “GLAD”
[110]. Log2 ratio thresholds for low-level gain and heterozygous loss were set
at ±0.3. The R-package “Clonality” [111] was used to define the LR2 (likelihood
ratio with individual comparisons) and LR2 p-value and required copy number
data procession with the R-package “DNAcopy” [112]. 
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3.2.3 DNA methylation analysis
In Paper II, 16 samples were randomly selected to represent each clinical 
group (BM: bilateral-metachronous; BS: bilateral-synchronous; IM: 
ipsilateral-metachronous; IS: ipsilateral-synchronous) with four samples 
corresponding to two patients per group. Purified genomic DNA was 
processed at the SNP&SEQ technology platform, Uppsala, Sweden, using 
Illumina Infinium MethylationEPIC BeadChips (MethylationEPIC_v-1-0; 
mapped to UCSC Feb 2009 hg19: GRCh37). Raw data (IDAT files) were 
processed with the R-package “RnBeads” [113]. The probes were normalized 
using BMIQ (beta mixture quantile dilation) [114]. Beta values were obtained 
through “RnBeads”, while intensity values were extracted using the R-
package “ChAMP” to generate segmented copy number data for the segment 
analysis [115, 116]. The R-package “conumee” was used to extract 
unsegmented information of CNAs on the probe level [117]. The 
unsegmented CNAs were used for the Similarity Index (SI), the distance 
measure and the clustering analysis. 
3.2.4 Genome-wide SNP genotyping analysis
In Paper II, genome-wide SNP genotyping analysis for six tumours (three 
tumour pairs) was processed with Illumina Infinium HumanOmni2.5-8 v1.3 
BeadChips at SCIBLU, Sweden. B-allele frequencies (BAF) and logR ratios (LRR) 
were calculated using the Illumina GenomeStudio Genotyping Module 
software (V2011.1) and hg19 build 37 reference assembly of the human 
genome.  
3.2.5 Whole transcriptome RNA sequencing (RNA-seq)
In Paper II, total RNA of six tumours (three tumour pairs) were processed at 
SciLifeLab, Sweden. Illumina TruSeq strand-specific RNA libraries (Ribosomal 
depletion using RiboZero human) containing 125 bp paired-end reads were 
obtained for each sample on a HiSeq2000 sequencer (Illumina). Data 
processing was performed as described previously [118]. In brief, data was 
processed using FastQC (0.11.5) for quality control of raw RNA-seq reads, 
TrimGalore (0.3.3) to trim and filter RNA-seq reads, and STAR (2.5.1b) for 
alignment to the hg19 build 37 reference assembly of the human genome 
yielding approximately 40-50 million aligned reads per sample. HtSeq (0.6.1) 
[119] and Cufflinks (2.2.1) [120] were applied to calculate counts and
fragments per kilobase of transcript per million mapped reads (FPKM),
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respectively. Quality control statistics for mapped reads were obtained using
RSeQC (2.3.6).
Fusion transcripts were identified with FusionCatcher (0.99.5a) [121] using 
criteria to remove false positive candidate fusion events, followed by
classification of “driver” fusion events (Bayesian probability scores <0.5) with
oncogenic potential using Oncofuse (1.1.1) [122]. Genetic variants were
identified and annotated using the Genome Analysis Toolkit (GATK 3.5.0)
variant calling pipeline [123] and ANNOVAR (2016.05.11). Common genetic
variants found in the human population were removed with ANNOVAR using
the dbSNP (hg19_snp138) and 1000 Genomes Project databases
(1000g2015aug) with a minor allele frequency (MAF) threshold of 0.01.
3.2.6 OncoScan CNV Plus Assay
In Paper III, 36 breast cancer samples from the Swedish haemangioma cohort
were processed at the Array and Analysis Facility (Uppsala, Sweden) using the
OncoScan CNV Plus Assay (Affymetrix), which identifies CNAs, loss of 
heterozygosity and somatic mutations. Array fluorescence intensity data (CEL
files) were combined using the Chromosome Analysis Suite (ChAS; version:
3.3.0.139) to produce OSCHP files. The MAPD (Median of the Absolute Values
of all Pairwise Differences) is a QC metric generated by ChAS and works as a
global measure for variation in the microarray probes that is ideally below 0.3 
but ranged between 0.287-0.398 for our samples [124]. The ndSNPQC (SNP
Quality Control of Normal Diploid Markers) measures how well genotype
alleles are resolved in the microarray data and ranged between 15.313-
46.021 (ideally ndSNPQC ≥26) [124]. These shortcomings in quality were
accounted for by the R-package “TAPS” (Tumour Aberration Prediction Suite;
v.2.0) that generated quality metrics based on allele-specific copy number
data [125]. “TAPS” detects chromosomal aberrations with higher sensitivity
even for tumours with a low proportion of tumour cells by integrating allelic
data [125]. Five samples were excluded based on the “TAPS” visualization of
chromosomal aberrations, while the remaining 31 samples were analysed
using R (v.3.5.1) [126] and Nexus Express Software for OncoScan 3.1
(BioDiscovery; Build version: 9289). In the Nexus Express analyses, combined
regions of DNA gains and losses were stratified by high- and low-dose groups
(p-value cut-off: 0.05; differential threshold: 25%; minimum segment size to
detect copy number gains and losses, allelic imbalances, and LOH: 500 kb;
minimum probes per segment: 20). Combined regions with >90% overlap
with CNVs were removed.
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3.2.3 DNA methylation analysis
In Paper II, 16 samples were randomly selected to represent each clinical
group (BM: bilateral-metachronous; BS: bilateral-synchronous; IM: 
ipsilateral-metachronous; IS: ipsilateral-synchronous) with four samples
corresponding to two patients per group. Purified genomic DNA was
processed at the SNP&SEQ technology platform, Uppsala, Sweden, using 
Illumina Infinium MethylationEPIC BeadChips (MethylationEPIC_v-1-0;
mapped to UCSC Feb 2009 hg19: GRCh37). Raw data (IDAT files) were
processed with the R-package “RnBeads” [113]. The probes were normalized
using BMIQ (beta mixture quantile dilation) [114]. Beta values were obtained
through “RnBeads”, while intensity values were extracted using the R-
package “ChAMP” to generate segmented copy number data for the segment
analysis [115, 116]. The R-package “conumee” was used to extract
unsegmented information of CNAs on the probe level [117]. The
unsegmented CNAs were used for the Similarity Index (SI), the distance 
measure and the clustering analysis.
3.2.4 Genome-wide SNP genotyping analysis
In Paper II, genome-wide SNP genotyping analysis for six tumours (three
tumour pairs) was processed with Illumina Infinium HumanOmni2.5-8 v1.3
BeadChips at SCIBLU, Sweden. B-allele frequencies (BAF) and logR ratios (LRR)
were calculated using the Illumina GenomeStudio Genotyping Module
software (V2011.1) and hg19 build 37 reference assembly of the human
genome.
3.2.5 Whole transcriptome RNA sequencing (RNA-seq)
In Paper II, total RNA of six tumours (three tumour pairs) were processed at 
SciLifeLab, Sweden. Illumina TruSeq strand-specific RNA libraries (Ribosomal
depletion using RiboZero human) containing 125 bp paired-end reads were
obtained for each sample on a HiSeq2000 sequencer (Illumina). Data
processing was performed as described previously [118]. In brief, data was
processed using FastQC (0.11.5) for quality control of raw RNA-seq reads,
TrimGalore (0.3.3) to trim and filter RNA-seq reads, and STAR (2.5.1b) for
alignment to the hg19 build 37 reference assembly of the human genome
yielding approximately 40-50 million aligned reads per sample. HtSeq (0.6.1)
[119] and Cufflinks (2.2.1) [120] were applied to calculate counts and
fragments per kilobase of transcript per million mapped reads (FPKM),
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respectively. Quality control statistics for mapped reads were obtained using 
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chromosomal aberrations, while the remaining 31 samples were analysed
using R (v.3.5.1) [126] and Nexus Express Software for OncoScan 3.1
(BioDiscovery; Build version: 9289). In the Nexus Express analyses, combined
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with CNVs were removed.
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3.3 Bioinformatics and statistical analysis
Statistical analyses were performed in the open-source programming 
environment R [126] using two-sided tests and a 0.05 p-value cut-off, unless 
stated otherwise. 
3.3.1 Paper I
3.3.1.1 Multivariable predictive modelling
First, univariable Cox proportional hazards models were fitted for each probe 
on the gene expression microarray using the R-package “survival” (v2.40-1) 
[127]. A total of 9,159 transcripts in the training cohort (n = 136) were 
identified as significantly associated with DSS. Second, adjusting for multiple 
testing using Bonferroni correction reduced the number of significant 
transcripts to 186. Third, iterative BMA (R-packages “BMA” (v3.18.7) [128] 
and “iterativeBMAsurv” (v1.32.0) [38]) was used to further reduce the 
number of transcripts to an 18-marker panel.  
3.3.1.2 Survival analysis and predictive power
Hazard ratios were obtained by fitting univariable and multivariable Cox 
proportional hazard models for each cohort using the R-package “survival” 
(v2.40-1) [127]. Patients were stratified into high- and low-risk groups 
according to the linear predictor η (eta) which represents the product of the 
covariate vector 𝑥𝑥𝑥𝑥 (gene expression) and the parameter vector β (Cox 
coefficient). Patients with η >0 were classified as high-risk patients and those 
with η <0 as low-risk patients. If η equals 0, the patient cannot be classified in 
the high- or low-risk groups, because a HR of 1 means the covariate has no 
effect on the model. Kaplan-Meier plots were generated using the R-package 
“survminer” (v0.2.2) [129]. 
AUC(t) statistics and C-indices were calculated using the R-package 
“risksetROC” (v1.0.4) [130] to assess the predictive power of the 18-marker 
model, the established marker model and the combined model (18 markers 
and established markers) based on the linear predictor as a marker [41, 42]. 
Since complete clinical information is needed for the combined models, only 
patients with complete information were used for the training and validation 
cohorts. 
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3.3.1.3 Oncotype Dx analysis
The commercially available Oncotype Dx is a qRT-PCR-based (quantitative
real-time reverse-transcriptase polymerase chain reaction) 21-gene signature
that includes 16 cancer-related genes and 5 reference genes for
normalization [28]. A multivariable model was fitted based on gene
expression microarray data of the training cohort using the 16 cancer-related
genes. The C-indices and AUC(t) functions were obtained as described above.
Bootstrapping was performed with 1,000 iterations comparing the 18-marker 
panel to the Oncotype Dx–based 16-gene signature. The model was applied
to the whole cohort and the ER-positive subcohort as Oncotype Dx is only
clinically validated for ER-positive breast carcinomas.
3.3.1.4 Pathway analysis
The interaction between the 18 candidate genes was analysed with the
Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems) using Fisher’s
exact test (significance threshold at P <0.05). The diseases and bio functions
tool was used to detect diseases and disorders that are associated with the
18 genes as well as molecular and cellular functions that overlap with the 18
genes. 
3.3.2 Paper II 
3.3.2.1 Similarity Index (SI)
The underlying assumption of the SI is that two tumours that share a higher
degree of patient-specific CNAs than two randomly paired tumours are
considered clonally related [53]. A permutation-based approach can ensure
that the shared CNAs between two tumours outweigh the recurrent 
chromosomal aberrations commonly found in breast cancer [53]. By 
calculating the similarities for artificial pairings of tumours from different
patients, we could approximate the reference distribution of similarities due
to recurrent aberrations or randomness, which allows us to reject the null
hypothesis if the SI exceeds its 95th percentile [53]. Normalized DNA copy
number data were discretized into loss (log2 ratio <-0.3), normal, and gain
(log2 ratio >0.3). Unique (NU), shared (NS), and opposite (NO) changes were
calculated for each combination of tumours to obtain the SI ranging between
0 (completely different) and 1 (identical genomic profiles): 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑁𝑁𝑁𝑁𝑆𝑆𝑆𝑆
𝑁𝑁𝑁𝑁𝑆𝑆𝑆𝑆 + 𝑁𝑁𝑁𝑁𝑈𝑈𝑈𝑈 + 𝑁𝑁𝑁𝑁𝑂𝑂𝑂𝑂
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For SI application on gene expression microarray data, the SI remained 
unchanged discretising normalized log2 ratios using a 1.5 fold change cut-off 
(underexpressed (log2 ratio <-0.58); neutral; overexpressed (log2 ratio >0.58)). 
For SI application on DNA methylation array data, the SI was modified (SImet) 
because the SI for copy number data is based on measuring the amount of 
alterations from the biologically neutral state (two copies per allele). For DNA 
methylation however, neither methylated nor unmethylated can be defined 
as the neutral state of a cytosine. In the SImet, beta values were discretized 
according to thresholds defined by Du et al. [131] into methylated (beta value 
>0.8), unmethylated (beta value <0.2), and hemimethylated (beta value
range: 0.2-0.8). The SImet counts the number of probes with shared
methylation states between two tumours and divides it by the total number
of probes, which provides the percentage of shared methylation states.
3.3.2.2 Hierarchical clustering
Unsupervised hierarchical clustering was performed using single linkage with 
Euclidean distance as proposed by Ostrovnaya and colleagues [132]. Clonality 
was defined as two tumours from the same patient clustering together in the 
terminal branch of the dendrogram.  
3.3.2.3 Distance measure
Distance matrices of the Euclidean distances between different tumour 
samples were computed using the basic “stats” R-package [126]. The 
reference distribution of distances was approximated by calculating the 
distance measure for all possible combinations of tumour pairs. Tumour pairs 
that are more similar exhibit a shorter distance. Statistical significance for 
clonality was defined as the distance of a true tumour pair below the fifth 
percentile of the reference distribution. 
3.3.2.4 Shared segment analysis
Two clonally related tumours are expected to share some altered DNA 
segments. A shared segment was defined as an overlap of the exact loci in 
both ends of the segment with the same altered direction (increase or 
decrease in copy number). Clonality was defined as the number of shared 
segments above the 95th percentile of the reference distribution. 
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3.3.2.5 Mutation and fusion transcript analysis
Mutational changes that were identical in both tumours were counted for all
possible combinations of tumour pairs in genomic and exonic RNA-seq data
as well as in a panel of 254 breast cancer mutation spots [133]. Clonality was
defined as the number of shared mutations above the 95th percentile of the
reference distribution. The R-package “Clonality” [111] was applied to profiles
of somatic mutations with loci-specific mutation probabilities obtained from
the TCGA breast cancer dataset [105]. Furthermore, fusion transcripts of all
tumours were compared and transcripts with identical 5’ and 3’ fusion
partner breakpoints were counted with clonality being defined as the number
of shared fusion transcripts above the 95th percentile of the reference 
distribution. 
3.3.2.6 Cohen’s kappa
Cohen’s kappa was applied to measure the chance-corrected agreement of
two observations [134]. Cohen’s kappa indices of agreement were calculated
using the R-package “rel” [135] to detect the highest agreement between the 
different methods assessing clonality.
3.3.3 Paper III
3.3.3.1 Processing of DNA copy number data
Weighted log2 ratios and B allele frequencies generated by ChAS were
processed by the R-package “copynumber” (v.1.22.0) to obtain allele-specific
segmentation [136]. The number of segments was defined as the number of
allele-specific autosomal segments generated by “copynumber”. The FGA
(fraction of the genome altered) was defined as the number of autosomal
DNA gain or loss (log2 ratio cut-off: ±0.15) divided by the total number of
autosomal probes [137]. Allele-specific segments were used for
chromothripsis-like pattern (CTLP) detection using the web-based 
CTLPScanner (http://cgma.scu.edu.cn/CTLPScanner/; Genome assembly: 
GRCh37/hg19; CN status change times: ≥10; Log10 of likelihood ratio ≥8;
Minimum segment size (Kb): 50; Signal distance between adjacent segments:
0.3; Genomic gains and losses: ±0.15) [138]. The R-package “ASCAT” (allele-
specific copy number analysis of tumours; v.2.5) was used to assess tumour
purity, ploidy and allele-specific copy number profiles [139]. 
Patients and Methods
26 
For SI application on gene expression microarray data, the SI remained
unchanged discretising normalized log2 ratios using a 1.5 fold change cut-off 
(underexpressed (log2 ratio <-0.58); neutral; overexpressed (log2 ratio >0.58)).
For SI application on DNA methylation array data, the SI was modified (SImet) 
because the SI for copy number data is based on measuring the amount of
alterations from the biologically neutral state (two copies per allele). For DNA
methylation however, neither methylated nor unmethylated can be defined
as the neutral state of a cytosine. In the SImet, beta values were discretized 
according to thresholds defined by Du et al. [131] into methylated (beta value
>0.8), unmethylated (beta value <0.2), and hemimethylated (beta value
range: 0.2-0.8). The SImet counts the number of probes with shared
methylation states between two tumours and divides it by the total number
of probes, which provides the percentage of shared methylation states.
3.3.2.2 Hierarchical clustering
Unsupervised hierarchical clustering was performed using single linkage with
Euclidean distance as proposed by Ostrovnaya and colleagues [132]. Clonality
was defined as two tumours from the same patient clustering together in the
terminal branch of the dendrogram.
3.3.2.3 Distance measure
Distance matrices of the Euclidean distances between different tumour
samples were computed using the basic “stats” R-package [126]. The
reference distribution of distances was approximated by calculating the
distance measure for all possible combinations of tumour pairs. Tumour pairs
that are more similar exhibit a shorter distance. Statistical significance for
clonality was defined as the distance of a true tumour pair below the fifth
percentile of the reference distribution.
3.3.2.4 Shared segment analysis
Two clonally related tumours are expected to share some altered DNA
segments. A shared segment was defined as an overlap of the exact loci in
both ends of the segment with the same altered direction (increase or
decrease in copy number). Clonality was defined as the number of shared
segments above the 95th percentile of the reference distribution. 
Patients and Methods 
27 
3.3.2.5 Mutation and fusion transcript analysis
Mutational changes that were identical in both tumours were counted for all 
possible combinations of tumour pairs in genomic and exonic RNA-seq data 
as well as in a panel of 254 breast cancer mutation spots [133]. Clonality was 
defined as the number of shared mutations above the 95th percentile of the 
reference distribution. The R-package “Clonality” [111] was applied to profiles 
of somatic mutations with loci-specific mutation probabilities obtained from 
the TCGA breast cancer dataset [105]. Furthermore, fusion transcripts of all 
tumours were compared and transcripts with identical 5’ and 3’ fusion 
partner breakpoints were counted with clonality being defined as the number 
of shared fusion transcripts above the 95th percentile of the reference 
distribution. 
3.3.2.6 Cohen’s kappa
Cohen’s kappa was applied to measure the chance-corrected agreement of 
two observations [134]. Cohen’s kappa indices of agreement were calculated 
using the R-package “rel” [135] to detect the highest agreement between the 
different methods assessing clonality. 
3.3.3 Paper III
3.3.3.1 Processing of DNA copy number data
Weighted log2 ratios and B allele frequencies generated by ChAS were 
processed by the R-package “copynumber” (v.1.22.0) to obtain allele-specific 
segmentation [136]. The number of segments was defined as the number of 
allele-specific autosomal segments generated by “copynumber”. The FGA 
(fraction of the genome altered) was defined as the number of autosomal 
DNA gain or loss (log2 ratio cut-off: ±0.15) divided by the total number of 
autosomal probes [137]. Allele-specific segments were used for 
chromothripsis-like pattern (CTLP) detection using the web-based 
CTLPScanner (http://cgma.scu.edu.cn/CTLPScanner/; Genome assembly: 
GRCh37/hg19; CN status change times: ≥10; Log10 of likelihood ratio ≥8; 
Minimum segment size (Kb): 50; Signal distance between adjacent 
segments: 0.3; Genomic gains and losses: ±0.15) [138]. The R-package 
“ASCAT” (allele-specific copy number analysis of tumours; v.2.5) was used to 
assess tumour purity, ploidy and allele-specific copy number profiles [139]. 
Patients and Methods 
28 
3.3.3.2 G2I (Genomic instability index)
The G2I algorithm applies a two-parameter index based on the global level of 
genomic alteration (TXP: altered probes / total probes) and the number of 
altered genomic regions (NB: local score statistics for altered genomic 
regions) [140]. G2I uses differential survival data to define the cut-off that 
separates the samples into stable (G2I-1 and G2I-2) and unstable (G2I-3) 
tumour genomes [140]. The G2I algorithm was performed on copy number 
data (discretized with ±0.15 log2 ratio cut-offs) using the R scripts provided by 
Bonnet and colleagues [140]. 
3.3.3.3 Complex arm-wise aberration index (CAAI) 
The CAAI score is a validated prognostic marker in breast cancer that captures 
focal DNA alterations (i.e. narrow peaks of high copy number gains), which 
represent the degree of local distortion [141, 142]. Samples were classified as 
CAAI positive if the CAAI score exceeded the threshold 0.5 in at least one 
chromosome arm of the sample [141, 142]. Since the CAAI algorithm 
classified all samples in the haemangioma cohort as unstable, we applied 
three CAAI-related metrics to represent tendencies of genomic instability 
(average score, number of unstable arms, and maximum CAAI score). 
3.3.3.4 GII (Genomic instability index)
The GII is defined as the FGA relative to the baseline ploidy of the sample 
[143]. A threshold of GII = 0.2 was used to distinguish genomically stable from 
unstable tumours, as previously defined [144, 145]. 
3.3.3.5 Survival analysis
The R-package “survival” (v.2.43-3) was used to fit Cox models and C-indices 
were calculated using the R-package “risksetROC” (v.1.0.4). The R-package 
“survminer” (v.0.4.3) was used to generate Kaplan-Meier plots that were 
based on (i) the G2I classification and (ii) the linear predictor η of the 
interaction model combining the effects of the G2I classification and the 
absorbed dose (G2I* absorbed dose; equivalent to: G2I + absorbed dose + 
G2I:absorbed dose). Patients with η >0 were classified as poor-prognosis 
patients and η <0 as good-prognosis patients. The survival data complied with 
the proportional hazards assumption for fitting Cox models. 
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4 RESULTS AND DISCUSSION
4.1 Paper I
4.1.1 Identification of the 18-marker panel
In the training cohort, 9,159 transcripts were significantly associated with DSS
in univariable Cox models. Adjusting for multiple testing reduced the number
of transcripts to 186, which was further narrowed down to 18 genes using
iterative BMA. Nine of the 18 genes (ACAA1, BORCS6, CCNA2, CDCA5,
FAM91A1, KIAA0494, MTURN, NEIL3, and TRIP13) displayed a HR <1 and were
thus negatively associated with breast cancer-specific mortality (Figure 6). 
The remaining nine genes (ADGRG6, CDKN2A, HJURP, HSPA14, LRRCC1,
PRR11, SKA2, SNX8, and STAM) had an unfavourable effect on survival, i.e. 
positive association with breast cancer-specific mortality. CDKN2A was the
only gene that was not significant (P = 0.059) in the multivariable model but
was kept in the model due to its strong contribution to the predictive power.
The strength of the model is that the marker selection was unbiased and
presented a good trade-off between parsimony and predictive capacity.
Pathway analysis showed that the molecular and cellular functions of the 18
markers included cell cycle, cellular assembly and organization, and DNA
replication, recombination and repair. Hence, the unbiased statistical
approach of marker selection identified biologically meaningful markers
without including previous biological knowledge.
Figure 6. Forest plot depicting the hazard ratios (HRs) of the multivariable 18-marker panel in 
the training cohort. HRs above one indicate that a gene is positively associated with breast
cancer-specific mortality. The box size is based on precision, where a bigger box size represents
a more precise confidence interval (95% CI). The x-axis is plotted on logarithmic scale. 
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3.3.3.5 Survival analysis
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based on (i) the G2I classification and (ii) the linear predictor η of the
interaction model combining the effects of the G2I classification and the
absorbed dose (G2I* absorbed dose; equivalent to: G2I + absorbed dose +
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patients and η <0 as good-prognosis patients. The survival data complied with
the proportional hazards assumption for fitting Cox models.
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4 RESULTS AND DISCUSSION
4.1 Paper I
4.1.1 Identification of the 18-marker panel
In the training cohort, 9,159 transcripts were significantly associated with DSS 
in univariable Cox models. Adjusting for multiple testing reduced the number 
of transcripts to 186, which was further narrowed down to 18 genes using 
iterative BMA. Nine of the 18 genes (ACAA1, BORCS6, CCNA2, CDCA5, 
FAM91A1, KIAA0494, MTURN, NEIL3, and TRIP13) displayed a HR <1 and were 
thus negatively associated with breast cancer-specific mortality (Figure 6). 
The remaining nine genes (ADGRG6, CDKN2A, HJURP, HSPA14, LRRCC1, 
PRR11, SKA2, SNX8, and STAM) had an unfavourable effect on survival, i.e. 
positive association with breast cancer-specific mortality. CDKN2A was the 
only gene that was not significant (P = 0.059) in the multivariable model but 
was kept in the model due to its strong contribution to the predictive power. 
The strength of the model is that the marker selection was unbiased and 
presented a good trade-off between parsimony and predictive capacity. 
Pathway analysis showed that the molecular and cellular functions of the 18 
markers included cell cycle, cellular assembly and organization, and DNA 
replication, recombination and repair. Hence, the unbiased statistical 
approach of marker selection identified biologically meaningful markers 
without including previous biological knowledge. 
Figure 6. Forest plot depicting the hazard ratios (HRs) of the multivariable 18-marker panel in 
the training cohort. HRs above one indicate that a gene is positively associated with breast 
cancer-specific mortality. The box size is based on precision, where a bigger box size represents 
a more precise confidence interval (95% CI). The x-axis is plotted on logarithmic scale. 
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4.1.2 Survival prognosis based on the 18-marker panel
Multivariable Cox models based on the linear predictor stratified all training 
and validation cohorts significantly into low- and high-risk groups (Figure 7). 
In the training cohort, 15 (79-patient subcohort; HR = 0.069; Figure 7A) and 
12 times (136-patient complete cohort; HR = 0.089; Figure 7B) as many 
patients died at any time in the high-risk group compared to the low-risk 
group. In the validation cohorts, the HR ranged from 0.417 for the TCGA 
dataset (Figure 7D) to 0.182 for RFS in the GSE1456 cohort (Figure 7G) 
representing 2-5 times as many deceased patients in the high-risk group 
compared to the low-risk group. All corresponding log-rank tests for the 
training and validation cohorts showed significant differences between the 
high- and low-risk groups confirming the universal applicability of the 18-
marker panel. 
4.1.3 High predictive power of combined model
To improve outcome prediction, multivariable models were fitted based on 
a) the 18 markers, b) established clinicopathological markers (patient age at
diagnosis, histological grade, number of positive axillary lymph nodes,
pathological tumour size, ER, PR and HER2 status), and c) a combined model
of the 18 markers and established markers (Table 3). In the training cohort,
the 18-marker model showed a C-index of 0.913 for DSS and 0.896 for OS.
Combining the 18-marker panel with the established markers further
improved the C-indices to 0.930 for DSS and 0.929 for OS. In the validation
cohorts, the combined model for DSS showed the highest C-index (GSE1456;
C-index: 0.829).
In the training cohort (n = 79), the AUC(t) function (Figure 8A) confirmed the 
accuracy of the 18-marker model over time and showed a higher predictive 
power than established clinicopathological markers. The combined model 
had the highest predictive power, which receded with time but remained 
above 0.8. The high C-index and robust trend of the AUC(t) function, even 
after 8 years of follow-up, confirmed the stability of the model. The AUC(t) 
functions for the GSE1456 validation cohort (Figure 8B) were stable over 
time. The 18-marker panel showed a superior performance in comparison to 
the established markers, while the combined model had the highest 
predictive power. Taken together, the 18-marker panel in connection with 
clinical parameters proved to be an independent predictive model for clinical 
outcome in breast cancer. 
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Figure 7. Kaplan-Meier analysis of the 18-marker panel in training and validation cohorts. The 
x-axes depict time after initial diagnosis and y-axes depict survival. A and B, Estimators of the
probability of DSS in the subset training cohort (n = 79) and complete training cohort (n = 136).
C, Estimators of the probability of OS in the subset training cohort (n = 79). D, Estimators of
the probability of OS in the TCGA cohort (n = 720). E, Estimators of the probability of DFS in
the GSE4922 cohort (n = 237). F-H, Estimators of the probability of DSS, RFS, and OS in the
GSE1456 cohort (n = 128).
Results and Discussion
30 
4.1.2 Survival prognosis based on the 18-marker panel
Multivariable Cox models based on the linear predictor stratified all training
and validation cohorts significantly into low- and high-risk groups (Figure 7). 
In the training cohort, 15 (79-patient subcohort; HR = 0.069; Figure 7A) and 
12 times (136-patient complete cohort; HR = 0.089; Figure 7B) as many
patients died at any time in the high-risk group compared to the low-risk
group. In the validation cohorts, the HR ranged from 0.417 for the TCGA
dataset (Figure 7D) to 0.182 for RFS in the GSE1456 cohort (Figure 7G) 
representing 2-5 times as many deceased patients in the high-risk group
compared to the low-risk group. All corresponding log-rank tests for the
training and validation cohorts showed significant differences between the
high- and low-risk groups confirming the universal applicability of the 18-
marker panel.
4.1.3 High predictive power of combined model
To improve outcome prediction, multivariable models were fitted based on
a) the 18 markers, b) established clinicopathological markers (patient age at
diagnosis, histological grade, number of positive axillary lymph nodes,
pathological tumour size, ER, PR and HER2 status), and c) a combined model
of the 18 markers and established markers (Table 3). In the training cohort,
the 18-marker model showed a C-index of 0.913 for DSS and 0.896 for OS.
Combining the 18-marker panel with the established markers further
improved the C-indices to 0.930 for DSS and 0.929 for OS. In the validation
cohorts, the combined model for DSS showed the highest C-index (GSE1456;
C-index: 0.829).
In the training cohort (n = 79), the AUC(t) function (Figure 8A) confirmed the
accuracy of the 18-marker model over time and showed a higher predictive
power than established clinicopathological markers. The combined model
had the highest predictive power, which receded with time but remained
above 0.8. The high C-index and robust trend of the AUC(t) function, even 
after 8 years of follow-up, confirmed the stability of the model. The AUC(t) 
functions for the GSE1456 validation cohort (Figure 8B) were stable over
time. The 18-marker panel showed a superior performance in comparison to
the established markers, while the combined model had the highest 
predictive power. Taken together, the 18-marker panel in connection with
clinical parameters proved to be an independent predictive model for clinical
outcome in breast cancer.
Results and Discussion 
31 
Figure 7. Kaplan-Meier analysis of the 18-marker panel in training and validation cohorts. The 
x-axes depict time after initial diagnosis and y-axes depict survival. A and B, Estimators of the 
probability of DSS in the subset training cohort (n = 79) and complete training cohort (n = 136). 
C, Estimators of the probability of OS in the subset training cohort (n = 79). D, Estimators of 
the probability of OS in the TCGA cohort (n = 720). E, Estimators of the probability of DFS in 
the GSE4922 cohort (n = 237). F-H, Estimators of the probability of DSS, RFS, and OS in the
GSE1456 cohort (n = 128).
Results and Discussion 
32 
4.1.4 Comparison of the 18-marker panel to Oncotype Dx
Oncotype Dx is a clinically validated 21-gene assay for patients with ER-
positive tumours based on qRT-PCR. To compare the 18-marker panel to the 
Oncotype Dx assay, we fitted a multivariable model based on a 16-gene 
subset (excluding normalization genes) using gene expression microarray 
data. The 18-marker panel showed a significantly higher predictive power 
than the Oncotype Dx-based gene signature when applied to the complete 
cohort (Figure 8C). Since Oncotype Dx is only validated for ER-positive 
tumours, AUC(t) functions were also generated for the ER-positive subcohort 
(Figure 8D), where the 18-marker panel showed a clearly higher predictive 
power. These results highlight the novelty and potential clinical benefit of the 
18-marker signature, which not only exceeds the predictive power of the
established clinical markers, but also the predictive power of the clinically
validated Oncotype Dx signature.
4.1.5 Limitations of the study
A major limitation of the study is the lack of complete clinical information for 
the established markers in the training cohort, reducing the cohort to a 79-
patient subcohort for the multivariable modelling. 
Table 3. C-indices of the multivariable models (18 markers, established markers, and combined 
model). 
18 markers Established markers Combined model
Training
DSS 0.913 0.767 0.930
OS 0.896 0.778 0.929
TCGA
OS 0.665 0.631 0.699
GSE4922
DFS 0.686 0.625 0.719
GSE1456
DSS 0.803 0.707 0.829
RFS 0.754 0.678 0.769
OS 0.748 0.655 0.767
Cohort
Validation
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Furthermore, the training and microarray-based validation cohorts originated
from Swedish Cancer Registry studies, thereby overrepresenting the Swedish
population in this study. Another limitation is the comparison of probes from
different microarray platforms (Illumina Human HT-12 Whole-Genome
Expression BeadChip and Affymetrix Human Genome U133 Set). In most 
cases, the probes on the two microarray platforms did not map to the same
parts of the transcript sequence, while the TCGA mRNA-seq dataset 
represented a different type of RNA-based experiment. Nevertheless, true
biological effects should be detectable irrespective of the platform or type of
experiment used to analyse gene expression. 
Figure 8. AUC(t) functions of multivariable models. The lines represent the time-dependent
area under the ROC curve (AUC(t)) for the 18-marker panel (grey), the established markers
(blue), the combined model (red), and the Oncotype Dx-based 16-marker model (green). A,
Estimated performance of the training cohort for DSS (n = 79). Established clinical variables
contain patient age at diagnosis, histologic grade, number of positive axillary lymph nodes,
pathologic tumour size, ER, PR, and HER2 status. B, Estimated performance of GSE1456
validation cohort for DSS (n = 128). Established clinical variables contain histologic grade and 
subtype. C, Estimated performance of the 18-marker panel in comparison to the Oncotype Dx-
based 16-marker panel in the complete training cohort (n = 136) for DSS. D, Estimated
performance of the 18-marker panel in comparison to the Oncotype Dx-based 16-marker panel
in the ER-positive training cohort (n = 107) cohort for DSS. 
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4.2 Paper II
4.2.1 Histopathological discordances in tumour pairs
Discordant clinical factors were detected in 32% of tumour pairs (12/37). 
Changes in histological subtype were most prevalent (35% of tumour pairs; 
6/17), while molecular subtype differed in 25% of tumour pairs (2/8), ER 
status in 11% (4/35 patients), and HER2 status in 8% (3/37 patients). The 
discordant changes were equally distributed between the different clinical 
groups (BM: bilateral-metachronous; BS: bilateral-synchronous; IM: 
ipsilateral-metachronous; IS: ipsilateral-synchronous) and showed no 
statistical significance when stratified by group. 
4.2.2 Differential DNA copy number imbalances
Differential DNA copy number imbalances were identified in recurrent 
regions of DNA copy number gain (blue) and loss (red) comprising at least 25% 
of the tumours in the patient cohort (Figure 9). Very few differences in DNA 
copy number frequencies were found between synchronous and 
metachronous tumours with 59 significantly different genomic regions 
(Figure 9A). 
Figure 9. Genome-wide frequency plots of DNA copy number gains (blue) and losses (red) 
stratified by the time interval between the tumours (A, metachronous vs. synchronous) and 
the laterality (B, bilateral vs. ipsilateral). 
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Stratification by laterality resulted in 134 statistically significant regions of
DNA copy number imbalances with conspicuous losses on 8p and 11p in the
ipsilateral subgroup (Figure 9B). These results suggested that the anatomic
location had a greater influence on genomic diversity in the cohort than the
time interval between the tumours. 
4.2.3 DNA copy number as a tool for clonal relatedness
The SI applied to the aCGH data classified 46% of tumour pairs (17/37) as 
clonally related, which contradicted with current classification methods for
clonality using histopathology. The SI aims to assess the overlap between
CNAs in two tumours (Figure 10). Several molecular techniques, such as CGH 
(comparative genomic hybridization) [146, 147], aCGH [148, 149], as well as
whole exome and whole genome sequencing (WES and WGS, respectively)
[150-152], have been used to assess tumour clonality along with various
analytical tools [50, 51, 53, 146, 148, 153]. 
Figure 10. Overlay of DNA copy number profiles of two tumours from patient IS10 (A) and 
patient BS1 (B). CNAs of one tumour were plotted in black and CNAs of the other tumour in
grey to show similarities and differences between the two tumours from the same patient. The
SI classified the tumours of patient IS10 as clonally related based on the CNAs, while the
tumours of patient BS1 were classified as independent primary tumours.
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Currently, there is no consensus on which type of data and analysis method 
provide the most stable definition of clonality. In contralateral tumour pairs, 
Alkner et al. demonstrated clonal relatedness in 10% (1/10) of cases [152], 
which was lower than the clonal relatedness of bilateral tumours according 
to the SI in our cohort (29%, 5/17 tumour pairs). In a study on bilateral-
metachronous tumour pairs, Klevebring et al. found 12% (3/25) of cases to be 
clonally related [151], which was also lower than in our study (22%, 2/9 
tumour pairs). Direct comparisons of the rate of clonality between studies 
might vary due to differences in the study set-up, methods and statistics. 
However, in a cohort comprising ipsilateral-synchronous tumour pairs, 
Desmedt et al. defined 67% (24/36) of tumour pairs as clonal [154], which is 
comparable to the clonality rate of 64% (7/11 tumour pairs) in our study.  
4.2.4 DNA methylation as a tool for clonal relatedness
In Kruskal’s non-metric multidimensional scaling plot (MDS; Figure 11), beta 
values of synchronous samples showed a greater dissimilarity from each 
other as well as from other tumours of the cohort, while the metachronous 
samples formed a distinct cluster.  
Figure 11. Kruskal’s non-metric multidimensional scaling (MDS) plot of beta values from the 
DNA methylation cohort (n = 16). The MDS plot visualized similarities between the individual 
samples based on the Euclidean distance matrix. 
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DNA methylation array-derived intensity values offered another method to
generate copy number data but presented a more liberal type of data for 
clonality classification than aCGH-derived copy number data. Particularly in
the clustering analysis, the intensity data more frequently classified tumour
pairs as similar in comparison with other types of molecular data (Figure 12). 
Concordance in clonality assessment between the copy number data
generated from aCGH and DNA methylation array-generated intensity data
was observed in only 50% of the cohort (BM7, BS7, BS8, and IS4). An overlap
in the classification of clonality between DNA methylation beta values and
aCGH data was found in 63% of the tumour pairs (BM7, BS7, IM4, IM9, and
IS3), which is lower than in other studies [155, 156]. The small cohort size and
the dynamic nature of DNA methylation limited the conclusions that could be
drawn regarding the feasibility of using DNA methylation as a tool to assess
tumour clonality.
Figure 12. Classification of clonality based on statistical methods and type of data. Red boxes 
indicate that the analysis defined the tumour pair as clonal and blue boxes indicate 
independence of the tumours. BAF: B allele frequency; LRR: log R ratio; SI: Similarity Index;
SImet: modified SI for methylation data.
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4.2.5 Gene expression as a tool for clonal relatedness
The gene expression subcohort consisted of seven patients with ipsilateral 
tumours. All synchronous cases (4/4) were identified as clonal while 2/3 
metachronous cases were classified as independent tumours (Figure 12). 
Regardless of the statistical method used, consistent results were shown for 
clonality classification and were in line with the aCGH results (except for 
patient IM4). Ipsilateral synchronous tumour pairs were identified as clonal 
based on gene expression patterns indicating that gene expression is similar 
for tumour cells arising in the same breast at the same time. As gene 
expression is a highly dynamic process, it might depict the adjacent tumour 
microenvironment more than the underlying genetic clonal relatedness. 
4.2.6 Agreement between the methods
Cohen’s kappa indices were calculated to identify the agreement of clonality 
estimates between the different statistical methods. Hierarchical clustering 
and the SI showed the highest agreement for aCGH data (0.659 and 0.630, 
respectively). Hierarchical clustering is an unsupervised classification tool 
assuming that the number of clusters and their members are unknown, which 
is not the case in the assessment of clonality. Therefore, the SI is preferred 
over hierarchical clustering as it is easier to interpret and specifically designed 
for the comparison of two tumours from the same patient. The SI identified 
46% (17/37) of the tumour pairs as clonal (Figure 12) and often showed 
opposite tendencies compared to the histopathological concordances. 
Additionally, no significant association between the SI and the clinical 
classification was found (Wilcoxon rank sum test: PLaterality = 0.247; PSynchronicity 
= 0.095; analysis of variance (ANOVA): PClinical groups = 0.229), highlighting the 
alarming reality that there is very little connection between current clinical 
guidelines and the biology underlying tumour clonality. 
The assessment of clonality based on the SI and hierarchical clustering 
showed similar tendencies in the majority of patients. The distance measure 
gave comparable results but seemed to be a more conservative measure 
since fewer tumour pairs were classified as clonal. The shared segment 
analysis with the aCGH data clearly favoured the clonality hypothesis with 
defining 21/37 tumour pairs as clonal.  
In most cases, the type of molecular data presented similar tendencies 
regardless of the method applied. This leads to the underlying question of 
which biological process provides the most reliable evidence for clonality. 
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DNA methylation and gene expression are more dynamic than DNA mutations
and CNAs. Hence, similar DNA methylation and gene expression patterns
might represent responses to similar environmental factors. Tumour
evolution of subclones is hypothesized to lead to a mixed pattern of shared
and independent CNAs and DNA mutations [157], which advocates the use of
DNA-based data to assess clonality. On the other hand, tumours developing
in the same genetic background and environmental setting have been
hypothesized to accumulate more frequently similar patterns of DNA
mutations and CNAs, despite emerging as independent tumours [152, 158]. 
4.2.7 Limitations of the study
A major limitation of the study is the small cohort size, which limited the
conclusions that could be drawn. Particularly in permutation-based 
approaches, some subcohorts were too small to perform meaningful 
statistics. A further disadvantage of the permutation-based approach was
that it did not show a clear separation between the reference distribution and
the clonal tumour pairs from the same patient. Hence, some artificial tumour
pairs from different patients also showed statistical significance. Possible
explanations could be intratumour heterogeneity, advanced accumulation of
changes unique to the subclone, repeated occurrence of CNAs frequently
identified in breast cancer [159-161], or technical artefacts increasing
background noise [157]. Intratumour heterogeneity complicates clonality
analyses due to biological differences in different parts of a tumour and
subclone evolution, which presents a general disadvantage of bulk analyses. 
Single-cell DNA sequencing could help to avoid obstacles connected to
intratumour heterogeneity and contamination with normal cells. In aCGH,
contamination with normal cells can diminish the intensity of detected CNAs
and small cell populations might not be detected. However, by using only
samples that showed a tumour cell content of at least 70%, we ruled out that
a lack of clonal relatedness could be due to a lack of tumour cells.
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for the comparison of two tumours from the same patient. The SI identified
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which biological process provides the most reliable evidence for clonality.
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DNA methylation and gene expression are more dynamic than DNA mutations 
and CNAs. Hence, similar DNA methylation and gene expression patterns 
might represent responses to similar environmental factors. Tumour 
evolution of subclones is hypothesized to lead to a mixed pattern of shared 
and independent CNAs and DNA mutations [157], which advocates the use of 
DNA-based data to assess clonality. On the other hand, tumours developing 
in the same genetic background and environmental setting have been 
hypothesized to accumulate more frequently similar patterns of DNA 
mutations and CNAs, despite emerging as independent tumours [152, 158]. 
4.2.7 Limitations of the study
A major limitation of the study is the small cohort size, which limited the 
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the clonal tumour pairs from the same patient. Hence, some artificial tumour 
pairs from different patients also showed statistical significance. Possible 
explanations could be intratumour heterogeneity, advanced accumulation of 
changes unique to the subclone, repeated occurrence of CNAs frequently 
identified in breast cancer [159-161], or technical artefacts increasing 
background noise [157]. Intratumour heterogeneity complicates clonality 
analyses due to biological differences in different parts of a tumour and 
subclone evolution, which presents a general disadvantage of bulk analyses. 
Single-cell DNA sequencing could help to avoid obstacles connected to 
intratumour heterogeneity and contamination with normal cells. In aCGH, 
contamination with normal cells can diminish the intensity of detected CNAs 
and small cell populations might not be detected. However, by using only 
samples that showed a tumour cell content of at least 70%, we ruled out that 
a lack of clonal relatedness could be due to a lack of tumour cells. 
Results and Discussion 
40 
4.3 Paper III
4.3.1 Dose-dependent differences in genomic instability
CNAs were found in all analysed tumours and affected an average of 17.23 
chromosomes per tumour, while ranging between 7 and 23 affected 
chromosomes per tumour. Breast carcinomas in the low- and high-dose 
groups showed significantly different patterns of CNAs across the genome 
(Figure 13). The high-dose group encompassed statistically significant regions 
of copy number gains on chromosomes 2q, 4, 17, 21q, and 22q, as well as 
copy number losses on 6q in comparison with the low-dose group. 
In addition, the high-dose group showed a significantly higher number of total 
CNAs (Figure 14; P = 0.003) consistent with a higher fraction of the genome 
altered (FGA; P = 0.044). The TXP values (G2I-derived statistic; P = 0.048), the 
numbers of two or more copy gains (P = 0.019) and one copy losses (P = 0.035) 
were significantly increased in the high-dose group. Furthermore, a 
significantly higher percentage of the genome was changed in the high-dose 
group as compared to the low-dose group (Nexus-derived statistic; P = 0.019). 
These results suggest that a higher absorbed dose in the infant led to more 
complex genomic alterations in the breast tumour genome as an adult.  
The increased complexity of genomic alterations was manifested in an 
increase in the number of CNAs and a higher FGA and thereby a more 
unstable tumour genome. These findings demonstrated that dose-dependent 
biological changes can persist in a patient up to 80 years after irradiation and 
are consistent with previous studies on A-bomb survivors reporting increased 
numbers of CNAs as a hallmark of genomic instability [162]. 
Figure 13. Genome-wide frequency plots of DNA copy number gains (blue) and losses (red) 
stratified by the high-dose (n = 17) and low-dose groups (n = 14). 
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Other factors such as individual radiation sensitivity, exposure to other 
genotoxic stressors, or lifestyle choices in the subsequent decades might
confound the dose-dependent genomic instability to some extent [89]. 
However, Spearman’s rho (ρ) identified significant positive correlations 
between the absorbed dose and all three CAAI measures (average, number
of unstable arms, and maximum score) along with the number of 
chromosomal segments, one copy losses, two or more copy gains, and the
percentage of the genome changed. A strong correlation was found between
the total number of CNAs and the absorbed dose, further corroborating that 
a higher absorbed dose is associated with a more unstable genome. 
4.3.2 Increased occurrence of chromothripsis-like patterns
(CTLP regions)
Chromothripsis has been described in almost all cancer types with a
prevalence of approximately 2-3% [69] and about 0-21% in breast carcinomas
[163]. We detected a total of 12 CTLP regions in 29% of the patient samples
(9/31) presenting an increase in frequency. In most patients only one
Figure 14. Boxplots of molecular tumour features stratified by the high-dose (n = 17) and low-
dose groups (n = 14) with p-values calculated using Mann-Whitney U test.
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chromosome was affected, except for patient T13 (low-dose group) with 
three CTLP regions and patient T108 (high-dose group) with two regions. One-
third of the detected CTLP regions were on chromosome 11, which is a 
previously identified CTLP hotspot [138]. Contrarily, the occurrence of CTLPs 
was independent of the absorbed dose groups for the 31 patients included in 
this study (P = 0.456). A possible explanation could be the small cohort size. 
Furthermore, several mechanisms are hypothesized to cause chromothripsis, 
such as telomere attrition, and DSB generation by other exogenous agents or 
oncogene-induced replicative stress [164]. Therefore, chromothripsis might 
occur in some breast tumours of this cohort regardless of prior irradiation 
exposure.  
The exact mechanisms driving chromothripsis are still unknown. One theory 
proposes that chromothripsis is triggered through ionizing radiation during 
mitosis leading to DSBs in a narrow region of a chromosome or several 
chromosomes in close proximity [74, 75]. Subsequently, the resulting 
chromosome fragments could re-assemble in the consecutive G1 phase [75, 
164]. CTLPs can be induced artificially by ionizing radiation using proton 
microbeam irradiation [165]. The mechanism inducing chromothripsis is 
hypothesized to vary depending on the type of radiation exposure [165]. 
Accordingly, when the entire cell is irradiated (as assumed in the radium-226 
treatment), chromothripsis is thought to be induced via micronuclei 
formation. The increased occurrence of CTLPs in the Swedish haemangioma 
cohort could indicate that chromothripsis and genomic instability might be 
implemented through defects in similar pathways or mechanisms, such as 
micronuclei formation [165]. However, it remains unclear whether 
chromothripsis was a direct effect of radiation exposure or an indirect effect 
where radiation-activated factors lead to chromothripsis in subsequent 
decades. 
4.3.3 Interaction between absorbed dose and genomic 
instability
The G2I algorithm stratified the cohort with statistical significance in the 
univariable Cox model but had low predictive power (Figure 15A; P = 0.006; 
C-index: 0.656; AIC: 38.299). Inversely, the univariable Cox model fitted using
the absorbed dose showed no statistical significance but had high predictive
power (P = 0.1; C-index: 0.800; AIC: 34.978). Multivariable models were fitted
to investigate putative additive effects (G2I + absorbed dose) and possible
interactions between the two observations (Figure 15B; G2I * absorbed dose;
equivalent to: G2I + absorbed dose + G2I:absorbed dose).
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The interaction model of G2I and the absorbed dose exhibited the highest
predictive power and the lowest AIC. Furthermore, the interaction model
stratified all deceased patients into the poor prognosis group using the linear 
predictor η. As previously reported, a mechanistic model incorporating the
effects of radiation-induced genomic instability at an early stage of
carcinogenesis significantly improved the description of the radiation risk in
the Swedish haemangioma cohort [95, 97, 98]. Taken together, the
interaction model supported the hypothesis that radiation-induced genomic
instability forms the missing link to the dose-dependent risk of developing 
breast cancer in the Swedish haemangioma cohort.
4.3.4 Limitations of the study
This study had several limitations. First, the small sample size limited the
statistical power of the study. Second, the low DNA quality of FFPE samples
limited the range of assays that could be applied. Third, the OncoScan array
has a relatively low resolution ranging between 50-300 kb. Hence, the default
settings of the CTLPScanner were increased to a minimum segment size of 50
kb and lowered to copy number status change times ≥10, which is common
practice for array data [163]. Fourth, absorbed dose is a macrodosimetric
measure that is not considered optimal for the analysis and interpretation of
molecular events [166]. The availability of microdosimetric calculations would
have provided a more accurate basis for associations between genomic
instability and relative biological effectiveness of the radiation
microenvironment in breast tissue. Finally, it should be noted that from a
radiobiological perspective, absorbed doses around 1 Gy are considered
“moderate” and that doses above several Gray are categorized as “high”. 
Figure 15. Kaplan-Meier analysis stratified by (A) a univariable Cox model using G2I, and (B) 
the linear predictor of a multivariable Cox model comprising G2I, the absorbed dose and the
interaction variable (G2I:absorbed dose).
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5 CONCLUSIONS AND OUTLOOK
The 18-marker panel proved to be a robust classification model with high
predictive power that effectively stratified patients into low- and high-risk
prognosis groups. The predictive power was stable over time and gave the
best prediction in combination with established markers for DSS. Use of the
18-marker panel in conjunction with clinical parameters can help to
personalize treatment resulting in more aggressive therapy for high-risk
patients (reduce under-treatment) and less aggressive therapy for low-risk
patients (reduce over-treatment). Further research is needed to validate the
biological impact of the 18 markers on the protein level. Understanding the
interplay between these markers can facilitate the development of new
therapies for high-risk breast cancer patients.
The SI was identified as the most accurate tool to assess clonal relatedness in
breast tumour pairs by comparing the degree of similarity of an individual
tumour pair to a reference distribution. In the majority of the analyses, the
type of molecular data used had a stronger impact on the assessment of
clonality than the analytical method used. In metachronous cancer, tumour
clonality indicates insufficient treatment of the first tumour, hence, the
patient could benefit from a change in treatment regimen. A more accurate
classification of clonal relatedness may mitigate treatment failure and relapse
by integrating tumour-associated molecular features and clinical parameters.
Future research needs to define guidelines with exact thresholds to
standardize clonality testing in a routine diagnostic setting.
In the Swedish haemangioma cohort, we found biological indications for 
radiation-induced genomic instability persisting after exposure and ultimately
promoting carcinogenesis. Tumours from patients with higher absorbed dose
showed increased levels of genomic instability demonstrating the long-term
consequences of irradiation in humans. The highly predictive Cox regression
model incorporating the interaction between absorbed dose and genomic 
instability gave further evidence for radiation contributing to carcinogenesis
through genomic instability. However, the molecular mechanisms accounting
for persistence of genomic instability and its manifestation in breast
carcinomas remain unclear. Future research needs to investigate to which
degree micronucleus formation, ROS, and radiation-induced changes in DNA
methylation affect genome stability. This work gives a biological basis for
improved risk assessment to minimize carcinogenesis as a secondary disease
after radiation therapy.
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SAMMANFATTNING PÅ SVENSKA
Bröstcancer är den vanligaste cancertypen hos kvinnor med mer än 2 miljoner 
nya fall och cirka 627 000 bröstcancerrelaterade dödsfall i världen år 2018.
Flera gensignaturer har visat sig kunna förutsäga prognosen för
bröstcancerutfall och i vissa fall också kunna predicera effekter av olika
behandlingar. Nuvarande behandlingsriktlinjer fokuserar ännu främst på
etablerade patient- och tumörspecifika egenskaper och i mindre utsträckning 
på gensignaturer. Vi har identifierat en gensignatur baserad på uttrycket av
18 gener som gör att vi verkar kunna förutsäga bröstcancerspecifik
överlevnad mer exakt än med den kliniskt validerade Oncotype Dx-
signaturen.
Trots ökad överlevnad i bröstcancer under senare tid så får cirka 6-23% av
patienterna återfall inom fem år. Detta talar för behandlingssvikt vid den
initiala behandlingen. Det är mycket viktigt att skilja mellan återfall som beror
på klonal evolution och de som beror på nya primära tumörer. För närvarande
finns det ingen tydlig riktlinje för att avgöra om det är återfall med klonal
evolution eller en ny primär bröstcancer. Vi jämförde olika statistiska metoder
och datatyper och identifierade likhetsindexet (SI) som det mest pålitliga
verktyget för att klassificera tumörklonalt återfall.
Bröstkörteln är känd för att vara mycket känslig för joniserande strålning,
särskilt hos unga. Under åren 1920-1965 behandlades spädbarn med
joniserande strålning för hudhemangiom och uppföljning har visat en ökad
risk att utveckla bröstcancer senare i livet. Joniserande strålning har visat sig
inducera genomisk instabilitet. Därför analyserade vi brösttumörerna från
patienter i den svenska hemangiomkohorten för genomisk instabilitet.
Patienter med högre absorberade doser i bröstet uppvisade ökad genomisk
instabilitet jämfört med patienter som fick lägre doser. Strålningsinducerad
genomisk instabilitet kan vara förklaringen till att joniserande strålning i ung 
ålder kan leda till ökad risk för bröstcancer under de följande decennierna.
Sammanfattningsvis belyser detta arbete hur molekylärbiologi och statistiska
modeller kan öka möjligheterna till riskbedömningar i tillägg till redan
etablerade kliniska och patologiska faktorer. Detta gör att riskbedömningarna 
kan förbättras och med hjälp av det kan strategierna för 
bröstcancerbehandling anpassas till det bättre.
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Bröstcancer är den vanligaste cancertypen hos kvinnor med mer än 2 miljoner 
nya fall och cirka 627 000 bröstcancerrelaterade dödsfall i världen år 2018. 
Flera gensignaturer har visat sig kunna förutsäga prognosen för 
bröstcancerutfall och i vissa fall också kunna predicera effekter av olika 
behandlingar. Nuvarande behandlingsriktlinjer fokuserar ännu främst på 
etablerade patient- och tumörspecifika egenskaper och i mindre utsträckning 
på gensignaturer. Vi har identifierat en gensignatur baserad på uttrycket av 
18 gener som gör att vi verkar kunna förutsäga bröstcancerspecifik 
överlevnad mer exakt än med den kliniskt validerade Oncotype Dx-
signaturen.  
Trots ökad överlevnad i bröstcancer under senare tid så får cirka 6-23% av 
patienterna återfall inom fem år. Detta talar för behandlingssvikt vid den 
initiala behandlingen. Det är mycket viktigt att skilja mellan återfall som beror 
på klonal evolution och de som beror på nya primära tumörer. För närvarande 
finns det ingen tydlig riktlinje för att avgöra om det är återfall med klonal 
evolution eller en ny primär bröstcancer. Vi jämförde olika statistiska metoder 
och datatyper och identifierade likhetsindexet (SI) som det mest pålitliga 
verktyget för att klassificera tumörklonalt återfall. 
Bröstkörteln är känd för att vara mycket känslig för joniserande strålning, 
särskilt hos unga. Under åren 1920-1965 behandlades spädbarn med 
joniserande strålning för hudhemangiom och uppföljning har visat en ökad 
risk att utveckla bröstcancer senare i livet. Joniserande strålning har visat sig 
inducera genomisk instabilitet. Därför analyserade vi brösttumörerna från 
patienter i den svenska hemangiomkohorten för genomisk instabilitet. 
Patienter med högre absorberade doser i bröstet uppvisade ökad genomisk 
instabilitet jämfört med patienter som fick lägre doser. Strålningsinducerad 
genomisk instabilitet kan vara förklaringen till att joniserande strålning i ung 
ålder kan leda till ökad risk för bröstcancer under de följande decennierna. 
Sammanfattningsvis belyser detta arbete hur molekylärbiologi och statistiska 
modeller kan öka möjligheterna till riskbedömningar i tillägg till redan 
etablerade kliniska och patologiska faktorer. Detta gör att riskbedömningarna 
kan förbättras och med hjälp av det kan strategierna för 
bröstcancerbehandling anpassas till det bättre. 
